Embera adds $4.5 million in Series A cash

Embera NeuroTherapeutics says it has garnered $4.5 million in a continuation of its Series A financing. The money will go to development of new treatments for smoking cessation and other addictions. "This investment will enable us to complete preclinical development for EMB-001 and to bring this drug candidate entirely through a Phase I safety study," said CEO Bob Linke. Release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.